Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma - Maura C. Gillis, BA; Vanessa R. Weir, BA; Cecilia Lezcano, MD; Gopa Iyer, MD; Allison Gordon, MD (JAAD Case Reports)